Tommy Fornander

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: INTERNATIONAL JOURNAL OF CANCER. 2022;150(12):2072-2082

Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.

Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Article: JAMA NETWORK OPEN. 2021;4(6):e2114904

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.

Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
Article: MOLECULAR AND CLINICAL ONCOLOGY. 2021;14(5):94

IP6K2 predicts favorable clinical outcome of primary breast cancer.

Sandström J; Balian A; Lockowandt R; Fornander T; Nordenskjöld B; Lindström L; Pérez-Tenorio G; Stål O
Article: NPJ BREAST CANCER. 2021;7(1):2

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.

Løkkegaard S; Elias D; Alves CL; Bennetzen MV; Lænkholm A-V; Bak M; Gjerstorff MF; Johansen LE; Vever H; Bjerre C; Kirkegaard T; Nordenskjöld B; Fornander T; Stål O; Lindström LS; Esserman LJ; Lykkesfeldt AE; Andersen JS; Leth-Larsen R; Ditzel HJ
Article: MOLECULAR AND CLINICAL ONCOLOGY. 2020;12(5):415-420

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer.

Fohlin H; Bekkhus T; Sandström J; Fornander T; Nordenskjöld B; Carstensen J; Stål O
Article: ONCOLOGY LETTERS. 2020;19(1):52-60

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer.

Fohlin H; Bekkhus T; Sandström J; Fornander T; Nordenskjöld B; Carstensen J; Stål O
Article: JAMA ONCOLOGY. 2019;5(9):1304-1309

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

Yu NY; Iftimi A; Yau C; Tobin NP; van 't Veer L; Hoadley KA; Benz CC; Nordenskjöld B; Fornander T; Stål O; Czene K; Esserman LJ; Lindström LS
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2019;145(7):1845-1856

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.

Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2019;145(3):599-607

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.

Karlsson E; Veenstra C; Gårsjö J; Nordenskjöld B; Fornander T; Stål O
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(7):726-733

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS; Yau C; Czene K; Thompson CK; Hoadley KA; Van't Veer LJ; Balassanian R; Bishop JW; Carpenter PM; Chen Y-Y; Datnow B; Hasteh F; Krings G; Lin F; Zhang Y; Nordenskjöld B; Stål O; Benz CC; Fornander T; Borowsky AD; Esserman LJ; STO Trialists Group
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(1):17-27

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.

Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Article: BREAST CANCER RESEARCH AND TREATMENT. 2017;166(2):593-601

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
Article: JAMA ONCOLOGY. 2017;3(11):1503-1510

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
Article: ACTA ONCOLOGICA. 2017;56(4):614-617

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.

Rosell J; Nordenskjöld B; Bengtsson N-O; Fornander T; Hatschek T; Lindman H; Malmström P-O; Wallgren A; Stål O; Carstensen J
Article: LAKARTIDNINGEN. 2017;114:EED7

[Adverse reactions to anti-hormonal therapy affects adherence].

von Wachenfeldt A; Andersson A; Fornander T; Isaksson Friman E; Johnsson A; Uddbom E; Uttermalm A-C
Article: JOURNAL OF PATHOLOGY CLINICAL RESEARCH. 2017;3(1):38-43

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer.

Paulsson J; Rydén L; Strell C; Frings O; Tobin NP; Fornander T; Bergh J; Landberg G; Stål O; Östman A
Article: NPJ BREAST CANCER. 2017;3:28

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.

Schroeder B; Zhang Y; Stål O; Fornander T; Brufsky A; Sgroi DC; Schnabel CA
Article: BRITISH JOURNAL OF CANCER. 2016;115(11):1400-1407

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.

Colzani E; Clements M; Johansson ALV; Liljegren A; He W; Brand J; Adolfsson J; Fornander T; Hall P; Czene K
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2016;316(18):1888-1896

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Foukakis T; von Minckwitz G; Bengtsson N-O; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J; Swedish Breast Cancer Group (SweBCG), the German B
Article: BREAST CANCER RESEARCH AND TREATMENT. 2016;160(2):313-322

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Article: ONCOTARGET. 2016;7(24):37145-37159

Met and its ligand HGF are associated with clinical outcome in breast cancer.

Veenstra C; Pérez-Tenorio G; Stelling A; Karlsson E; Mirwani SM; Nordensköljd B; Fornander T; Stål O
Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2016;22:1-7

Can breast cancer register data on recommended adjuvant treatment be used as a proxy for actually given treatment?

Wennman-Larsen A; Nilsson MI; Saboonchi F; Olsson M; Alexanderson K; Fornander T; Sandelin K; Petersson L-M
Article: ONCOTARGET. 2016;7(16):21362-21380

EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer.

Husa A-M; Magić Ž; Larsson M; Fornander T; Pérez-Tenorio G
Article: CLINICAL CANCER RESEARCH. 2016;22(6):1421-1431

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S; Bostner J; Sun Y; Miller LD; Alayev A; Schwartz NS; Lager E; Fornander T; Nordenskjöld B; Yu JJ; Stål O; Holz MK
Article: BRITISH JOURNAL OF CANCER. 2016;114(3):248-255

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Hilborn E; Gacic J; Fornander T; Nordenskjöld B; Stål O; Jansson A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2015;47(4):1311-1320

HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.

Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
Article: BREAST CANCER RESEARCH AND TREATMENT. 2015;153(1):31-40

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.

Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
Article: ENDOCRINE-RELATED CANCER. 2015;22(3):331-343

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.

Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2015;141(5):797-804

The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.

Söderlund Leifler K; Asklid A; Fornander T; Stenmark Askmalm M
Article: BREAST CANCER RESEARCH. 2014;16(3):R53

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MPHM; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;145(1):61-71

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LMF; Fernö M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;145(1):73-82

C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

Hilborn E; Sivik T; Fornander T; Stål O; Nordenskjöld B; Jansson A
Article: CLINICAL CANCER RESEARCH. 2013;19(15):4196-4205

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

Zhang Y; Schnabel CA; Schroeder BE; Jerevall P-L; Jankowitz RC; Fornander T; Stål O; Brufsky AM; Sgroi D; Erlander MG
Article: ANNALS OF ONCOLOGY. 2013;24(8):1994-1999

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Weiner M; Skoog L; Fornander T; Nordenskjöld B; Sgroi DC; Stål O
Article: ONCOLOGIST. 2013;18(7):812-818

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.

Au H-J; Eiermann W; Robert NJ; Pienkowski T; Crown J; Martin M; Pawlicki M; Chan A; Mackey J; Glaspy J; Pintér T; Liu M-C; Fornander T; Sehdev S; Ferrero J-M; Bée V; Santana MJ; Miller DP; Lalla D; Slamon DJ; Translational Research in Oncology BCIRG 006 Trial
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;138(2):467-473

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.

Rosell J; Nordenskjöld B; Bengtsson N-O; Fornander T; Hatschek T; Lindman H; Malmström P-O; Wallgren A; Stål O; Carstensen J
Article: ONCOLOGY REPORTS. 2013;29(4):1467-1474

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

Göthlin Eremo A; Wegman P; Stål O; Nordenskjöld B; Fornander T; Wingren S
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(6):1196-1204

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
Article: BRITISH JOURNAL OF CANCER. 2013;108(5):1195-1208

Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study.

Walters S; Maringe C; Butler J; Rachet B; Barrett-Lee P; Bergh J; Boyages J; Christiansen P; Lee M; Wärnberg F; Allemani C; Engholm G; Fornander T; Gjerstorff ML; Johannesen TB; Lawrence G; McGahan CE; Middleton R; Steward J; Tracey E; Turner D; Richards MA; Coleman MP; ICBP Module 1 Working Group
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;137(1):297-305

Placental weight and mortality in premenopausal breast cancer by tumor characteristics.

Hajiebrahimi MH; Bahmanyar S; Lambe M; Adolfsson J; Fornander T; Wärnberg F; Cnattingius S
Article: BREAST CANCER RESEARCH. 2013;15(5):R96

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.

Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck A-L; Stål O
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(1):52-59

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Fahlén M; Fornander T; Johansson H; Johansson U; Rutqvist L-E; Wilking N; von Schoultz E
Article: LANCET ONCOLOGY. 2013;14(1):72-80

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla J-P; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay M-A; Wilson V; Rupin M; Houé V; Vogel C; TRIO/BCIRG 001 investigators
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;137(2):397-406

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(28):3478-3485

Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study.

Vichapat V; Garmo H; Holmqvist M; Liljegren G; Wärnberg F; Lambe M; Fornander T; Adolfsson J; Lüchtenborg M; Holmberg L
Article: BREAST CANCER RESEARCH AND TREATMENT. 2012;135(1):281-289

Impact of comorbidity on management and mortality in women diagnosed with breast cancer.

Berglund A; Wigertz A; Adolfsson J; Ahlgren J; Fornander T; Wärnberg F; Lambe M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2012;133(1):367-373

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.

Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Article: PLOS ONE. 2012;7(7):e40568

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

Sivik T; Gunnarsson C; Fornander T; Nordenskjöld B; Skoog L; Stål O; Jansson A
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;130(2):553-560

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.

Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Article: RADIOTHERAPY AND ONCOLOGY. 2011;100(2):167-175

Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden.

McGale P; Darby SC; Hall P; Adolfsson J; Bengtsson N-O; Bennet AM; Fornander T; Gigante B; Jensen M-B; Peto R; Rahimi K; Taylor CW; Ewertz M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;128(3):755-763

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.

Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;128(3):713-723

Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.

Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
Article: BRITISH JOURNAL OF CANCER. 2011;104(11):1762-1769

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall P-L; Ma X-J; Li H; Salunga R; Kesty NC; Erlander MG; Sgroi DC; Holmlund B; Skoog L; Fornander T; Nordenskjöld B; Stål O
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;126(2):421-430

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

Khoshnoud MR; Löfdahl B; Fohlin H; Fornander T; Stål O; Skoog L; Bergh J; Nordenskjöld B
Article: BRITISH JOURNAL OF CANCER. 2011;104(6):899-902

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial.

Rosell J; Nordenskjöld B; Bengtsson N-O; Fornander T; Hatschek T; Lindman H; Malmström P-O; Wallgren A; Stål O; Carstensen J
Article: WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION. 2011;38(4):337-346

Work status and life changes in the first year after breast cancer diagnosis.

Johnsson A; Fornander T; Rutqvist L-E; Olsson M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(6):1547-1554

Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer.

Söderlund Leifler K; Queseth S; Fornander T; Askmalm MS
Article: BREAST CANCER RESEARCH AND TREATMENT. 2010;121(3):679-683

Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

Lambe M; Wigertz A; Holmqvist M; Adolfsson J; Bardage C; Fornander T; Karlsson P; Odlind V; Persson I; Ahlgren J; Bergkvist L
Article: EUROPEAN JOURNAL OF CANCER CARE. 2010;19(3):317-323

Factors influencing return to work: a narrative study of women treated for breast cancer.

Johnsson A; Fornander T; Rutqvist LE; Olsson M
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2010;25(5):735-741

The impact of RNA standardization and heterogeneous gene expression on the results of cDNA array of human breast carcinoma.

Khoshnoud R; He Q; Sylván M; Khoshnoud A; Ivarsson M; Fornander T; Bergh J; Frisell J; Rutqvist L-E; Skog S
Article: CLINICAL CANCER RESEARCH. 2010;16(5):1624-1633

Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.

Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Article: BREAST CANCER RESEARCH. 2010;12(4):R53

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.

Jerevall P-L; Jansson A; Fornander T; Skoog L; Nordenskjöld B; Stål O
Article: BREAST CANCER RESEARCH AND TREATMENT. 2009;117(3):561-567

Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.

Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Article: BRITISH JOURNAL OF CANCER. 2009;101(6):902-907

Impact of tumour size on axillary involvement and distant dissemination in breast cancer.

Koscielny S; Arriagada R; Adolfsson J; Fornander T; Bergh J
Article: CLINICAL CANCER RESEARCH. 2009;15(10):3610-3616

Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2009;101(5):341-349

Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.

Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R
Article: ACTA ONCOLOGICA. 2009;48(1):93-98

Predictors of return to work ten months after primary breast cancer surgery.

Johnsson A; Fornander T; Rutqvist L-E; Vaez M; Alexanderson K; Olsson M
Article: ACTA ONCOLOGICA. 2009;48(1):86-92

Socioeconomic status and quality of life of women with family history of breast cancer attending an oncogenetic counseling clinic: a comparison with general population.

Von Wachenfeldt A; Brandberg Y; Johansson H; Fornander T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2007;107(1):71-78

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.

Khoshnoud MR; Fornander T; Johansson H; Rutqvist L-E
Article: ONCOGENE. 2007;26(49):6997-7005

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.

Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Article: RADIOTHERAPY AND ONCOLOGY. 2007;84(3):242-251

The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.

Söderlund K; Skoog L; Fornander T; Askmalm MS
Article: BRITISH JOURNAL OF CANCER. 2007;96(5):801-807

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.

Aubele M; Auer G; Walch AK; Munro A; Atkinson MJ; Braselmann H; Fornander T; Bartlett JMS
Article: ACTA ONCOLOGICA. 2007;46(1):90-96

Factors associated with return to work after breast cancer treatment.

Johnsson A; Fornander T; Olsson M; Nystedt M; Johansson H; Rutqvist LE
Article: FAMILIAL CANCER. 2006;5(4):309-321

Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County.

Margolin S; Johansson H; Rutqvist LE; Lindblom A; Fornander T
Article: ANTICANCER RESEARCH. 2006;26(6C):4753-4759

Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.

He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist L-E; Skog S
Article: EUROPEAN JOURNAL OF CANCER. 2006;42(7):895-904

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.

Baum M; Hackshaw A; Houghton J; Rutqvist; Fornander T; Nordenskjold B; Nicolucci A; Sainsbury R; ZIPP International Collaborators Group
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2005;16(6):979-985

Time-dependent RNA degradation affecting cDNA array quality in spontaneous canine tumours sampled using standard surgical procedures.

Von Euler H; Khoshnoud R; He Q; Khoshnoud A; Fornander T; Rutqvist L-E; Skog S
Article: ONCOLOGY REPORTS. 2005;14(4):1013-1019

Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.

He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2005;352(22):2302-2313

Adjuvant docetaxel for node-positive breast cancer.

Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla J-P; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C; Breast Cancer International Research Group 001 Inv
Article: MEDICAL ONCOLOGY. 2004;21(4):309-318

Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Löfgren L; Wallberg B; Wilking N; Fornander T; Rutqvist LE; Carlström K; von Schoultz B; von Schoultz E
Article: GENETIC TESTING AND MOLECULAR BIOMARKERS. 2004;8(2):127-132

BRCA1 mutations in a population-based study of breast cancer in Stockholm County.

Margolin S; Werelius B; Fornander T; Lindblom A
Article: TUMOR BIOLOGY. 2004;25(1-2):41-47

Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line.

Skog S; He Q; Khoshnoud R; Fornander T; Rutqvist L-E
Article: BRITISH JOURNAL OF SURGERY. 2003;90(9):1093-1102

Risk factors for local recurrence after breast-conserving surgery.

Fredriksson I; Liljegren G; Palm-Sjövall M; Arnesson L-G; Emdin SO; Fornander T; Lindgren A; Nordgren H; Idvall I; Holmqvist M; Holmberg L; Frisell J
Article: ANTICANCER RESEARCH. 2003;23(3C):3077-3083

Radiation-induced cell cycle response in lymphocytes is not related to clinical side-effects in breast cancer patients.

Tell R; Edgren MR; Sverrisdottir A; Castro J; Fornander T; Hansson L-O; Skog S; Lewensohn R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2003;21(9):1836-1844

Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.

Nystedt M; Berglund G; Bolund C; Fornander T; Rutqvist LE
Article: BRITISH JOURNAL OF SURGERY. 2002;89(7):902-908

Consequences of axillary recurrence after conservative breast surgery.

Fredriksson I; Liljegren G; Arnesson L-G; Emdin SO; Palm-Sjövall M; Fornander T; Holmqvist M; Holmberg L; Frisell J
Article: EUROPEAN JOURNAL OF CANCER. 2002;38(14):1860-1870

Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women.

Fredriksson I; Liljegren G; Arnesson L-G; Emdin SO; Palm-Sjövall M; Fornander T; Holmqvist M; Holmberg L; Frisell J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2001;68(3):199-210

Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose.

Lind PA; Wennberg B; Gagliardi G; Fornander T
Article: EUROPEAN JOURNAL OF CANCER. 2001;37(12):1537-1544

Time trends in the results of breast conservation in 4694 women.

Fredriksson I; Liljegren G; Arnesson LG; Emdin SO; Palm-Sjövall M; Fornander T; Frisell J; Holmberg L
Article: INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. 2000;15(2):139-146

The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.

He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Article: ACTA ONCOLOGICA. 2000;39(8):959-968

Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.

Nystedt M; Berglund G; Bolund C; Brandberg Y; Fornander T; Rutqvist LE
Article: ACTA ONCOLOGICA. 1999;38(5):597-601

Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival.

Billgren AM; Rutqvist LE; Tani E; Wilking N; Fornander T; Skoog L
Article: RADIOTHERAPY AND ONCOLOGY. 1998;49(3):245-254

Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning.

Lind PA; Rosfors S; Wennberg B; Glas U; Bevegård S; Fornander T
Article: BONE MARROW TRANSPLANTATION. 1998;22(5):445-448

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer.

Ljungman P; Björkstrand B; Fornander T; Höglund M; Juliusson G; Lindman H; Malmström A; Rotstein S; Söderberg M; Wilking N; Villman K; Bergh J
Article: RADIOTHERAPY AND ONCOLOGY. 1998;48(2):185-190

Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer.

Gyenes G; Rutqvist LE; Liedberg A; Fornander T
Article: EUROPEAN JOURNAL OF CANCER. 1998;34:S64

DNA content in tamoxifen-induced endometrial carcinoma

Moberger B; Fornander T; Hellstrom AC
Article: ANNALS OF ONCOLOGY. 1998;9(4):403-411

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

Bergh J; Wiklund T; Erikstein B; Fornander T; Bengtsson NO; Malmström P; Kellokumpu-Lehtinen P; Anker G; Bennmarker H; Wilking N
Article: JOURNAL OF CLINICAL ONCOLOGY. 1997;15(4):1348-1353

Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy.

Gyenes G; Gagliardi G; Lax I; Fornander T; Rutqvist LE
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(3):286-292

Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy.

Gyenes G; Fornander T; Carlens P; Glas U; Rutqvist LE
Article: ACTA ONCOLOGICA. 1997;36(5):509-515

A descriptive study of pulmonary complications after postoperative radiation therapy in node-positive stage II breast cancer.

Lind PA; Gagliardi G; Wennberg B; Fornander T
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1996;36(4):899-905

Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study.

Gyenes G; Fornander T; Carlens P; Glas U; Rutqvist LE
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1995;87(9):645-651

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

Rutqvist LE; Johansson H; Signomklao T; Johansson U; Fornander T; Wilking N
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1992;34(2):441-448

Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O
Visa fler

Alla övriga publikationer

Published conference paper: NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS. 2010;29(4-6):352-358

Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.

He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(18):3694-3699

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.

Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1998;34:s34

Multimodality therapy of 128 patients with locally advanced breast cancer in the era of mammography screening using standard FEC-prognostic and therapeutic implications

Karlsson Y; Malmström P; Hatschek T; Fornander T; Söderberg M; Bengtsson NO; Jansson T; Sjöberg S; Bergh J
Letter: AMERICAN HEART JOURNAL. 1996;131(6):1236-1238

Radiation-induced cardiac disease.

Gyenes G; Fornander T; Rutqvist LE

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027
Anknuten till Undervisning/Handledning, Onkologi-Patologi, Karolinska Institutet, 2021-2024

Examina och utbildning

Docent, onkologi, Karolinska institutet, 2003

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI